Sanofi to Make 125 Million BioNTech-Pfizer Vaccine Doses for EU


Every human life is precious and sacred and saving one is like saving the whole of humanity. (Al Quran 5:32/33)

Eiffel Tower the most well known landmark of France. The Muslim Times has the best and the latest about the Covid 19 vaccine

Source: Bloomberg

By Tim Loh, January 27, 2021, 3:01 AM EST

  •  Collaboration will help boost European Union’s vaccine supply
  •  Companies pledge more than 125 million doses of mRNA shot

Sanofi agreed to produce millions of doses of BioNTech SE and Pfizer Inc.’s coronavirus vaccine in an unusual collaboration to speed vaccination efforts.

The French drugmaker will give BioNTech access to a production facility in Frankfurt, which will start to deliver doses this summer, Sanofi said in a statement Wednesday. The deal will produce more than 125 million doses of the messenger RNA vaccine for the European Union.

Sanofi’s own effort to develop a vaccine with another big pharma firm, GlaxoSmithKline Plc, stumbled in clinical tests, meaning it won’t be ready by summer as expected. The production agreement allows the region to make up for some of the loss, accelerating the complex process of packaging and distributing a vaccine that needs to be kept at ultra-cold temperatures.

Pfizer and BioNTech have been looking for ways to increase the supply of their immunization, from expanding existing plants to adding suppliers and contract manufacturers.

Read further

Categories: Vaccine

2 replies

  1. A greater share of the American public wants to get a Covid-19 vaccine as soon as possible compared with those surveyed in December, a new poll found.

    Almost half of 1,563 adults surveyed expressed enthusiasm for getting the vaccine, up from 34% last month, according to a survey by the Kaiser Family Foundation. The share increased among Black, Hispanic and White adults.

    The Kaiser poll correlated enthusiasm for getting vaccinated with whether the respondent knows someone who has already received a dose. About half of those who want to get vaccinated knew someone who had, yet that factor varied along race and income lines.

  2. A Pfizer Inc. laboratory study found that coronavirus mutations identified in the U.K. and South Africa had only small impacts on the effectiveness of antibodies generated by the company’s Covid-19 vaccine.

    The antibodies were slightly less effective against mutations in the variant identified in South Africa, according to the study. It was posted Wednesday on the online server bioRxiv, which publishes scientific papers before they have been peer-reviewed.

    Researchers have been racing to assess whether Covid-19 vaccines and drugs will still work against new variants, as governments roll out shots they hope will allow schools, businesses and other establishments to reopen.

    Pfizer’s findings are consistent with other preliminary results reported in recent weeks by several research groups looking at the effectiveness of available vaccines against the new variants.

    The research is still preliminary, however. Pfizer’s study was conducted in a lab and tested only a subset of mutations found in the variants, but not the variants themselves. Also, the researchers didn’t assess whether their results were statistically significant.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.